Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
225Ac-lintuzumab in AML MRD
NCT03705858Phase 1Withdrawn
- Start
- Feb 2019
- Primary completion
- Feb 2019
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of lintuzumab satetraxetan ac-225 in acute myeloid leukemia (AML). Primary endpoint: Maximum Tolerated Dose up to 2 years. Planned start Feb 2019; status: withdrawn.
02
Drugs
lintuzumab satetraxetan ac-225
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03705858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03705858.